Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996562 | 0.78 | POLB (0.54) | MEN1POLBKMT2A | |
| SCHEMBL6996931 | 0.78 | CHRM1 (0.52) | CCR3 | |
| SCHEMBL6995970 | 0.77 | CCR1 (0.47) | — | |
| SCHEMBL6761241 | 0.76 | NAAA (0.45) | EPHX2HRH3 | |
| SCHEMBL6761237 | 0.76 | NAAA (0.45) | EPHX2HRH3 | |
| SCHEMBL6996406 | 0.73 | CCR1 (0.42) | MEN1POLBKMT2ACCR3 | |
| SCHEMBL6998823 | 0.72 | CCR1 (0.46) | MEN1POLBKMT2ACCR3 | |
| SCHEMBL7001971 | 0.72 | MEN1 (0.38) | MEN1POLBKMT2ACCR3 | |
| Bicarbonate SCHEMBL9362828 | 0.71 | EPHX2 (0.52) | MEN1POLBKMT2ACCR3EPHX2 | |
| SCHEMBL1761030 | 0.69 | MEN1 (0.55) | MEN1POLBKMT2ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | MEN1 4425/4885POLB 3658/4885KMT2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.